替米沙坦氢氯噻嗪对高血压患者血压变异性的影响被引量：3

下载PDF

导出

摘要目的观察替米沙坦氢氯噻嗪对原发性高血压患者血压变异性的影响。方法原发性轻中度高血压患者158例,分为勺形高血压组76例和非勺形高血压组82例,分别给予替米沙坦氢氯噻嗪胶囊1或2粒(每粒含替米沙坦40 mg,氢氯噻嗪12.5 mg),po,qd,治疗8周后监测动态血压。结果治疗前,与非勺形高血压组比较,勺形高血压组24 h、日间、夜间的收缩压(SBP)、舒张压(DBP)标准差均显著降低(P<0.05);治疗后,两组24 h、日间、夜间的SBP、DBP标准差均显著降低(P<0.05),但两组之间差异无统计学意义(P>0.05)。结论替米沙坦氢氯噻嗪能有效降低高血压患者血压变异性。

作者潘维花李杰魏霞

机构地区北京市大兴区红星医院内科

出处《医药导报》 CAS 2015年第1期61-63,共3页 Herald of Medicine

关键词替米沙坦氢氯噻嗪高血压原发性变异性血压

分类号 R972.4 [医药卫生—药品] R544.1 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献8

1POULTER N R, WEDE H, DAHLOF B, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian CardiacOutcomes TriM-Blood Pressure Lowering Arm (ASCOT- BPLA) [J]. Lancet,2005,366(9489) :907-913.
2MCGILL J B, REILLY P A. Telmisartan plus hydrochloro- thiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a muhicenter, randomized, double-blind, placebo-controlled, parallel-group trial[J]. Clin Ther,2001,23(6) :833-850.
3中国高血压防治指南修订委员会.中国高血压防治指南(2010年修订版)[M].北京:人民卫生出版社,2011:1.
4魏宸铭,宋波,谈颂,许予明.血压变异性与卒中[J].国际脑血管病杂志,2012,20(4):295-299. 被引量：6
5MANCIA G, GRASS! G. Mechanisms and clinical implica- tions of blood pressure variability [ J ]. Card Pharm, 2000,35 (7) :S15-S19.
6ETO M, TOBA K, AKISHITA M, et al. Impact of blood pressure variability on cardiovascular events in elderly patients with hypertension [ J ]. Hypertens Res,2005,28 ( 1 ) : 1-7.
7ROTHWELL P M, HOWARD S C, DOLAN E, et al. Effects of beta blockers and calcium-channel blockers on within- individual variability in blood pressure and risk of stroke [ J ]. Lancet Neurol, 2010 ,9 (5) :469-480.
8WEBB A J, FISCHER U, MEHTA Z, et al. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis [ J]. Lancet, 2010,375 (9718) :906-915.

二级参考文献43

1O'Donnell MJ, Xavier D, Liu L, et al; INTERSfROKE investigators. Risk factors for ischaemic and intracerebral haermrrhagic stroke in 22 countries (the INTERSfROKE study): a case-control study. Lancet, 2010,376: 112-123.
2Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drug; in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ, 2009, 338: b1665.
3Gorelick PB. Reducing blood pressure variability to prevent stroke? Lancet Neurol, 2010, 9: 448-449.
4Dolan E, 0 'Brien E. Blood pressure variability: clarity for clinical practice. Hypertension, 2010, 56: 179-181.
5Mancia G, Grassi G. Mechanisms and clinical implications of blood pressure variability. J Cardiovasc Pharrnacol, 2000, 35(7 SuppI4): S15-S19.
6Mancia G, Ferrari A, Gregorini L, et al. Blood pressure and heart rate variabilities in normotensive and hypertensive human beings. Circ Res, 1983,53: 96-104.
7Sega R, Cesana G, Bombelli M, et al. Seasonal variations in horne and ambulatory blood pressure in the PAMELA population. Pressione Arteriose Monitorate E Loro Associazioni. J Hypertens, 1998, 16: 1585-1592.
8Bilo G, Giglio A, Styczkiewicz Ketal. A new method for assessing 24- h blood pressure variability after excluding the contribution of nocturna1 blood pressure full. J Hypertens, 2007, 25: 2058-2066.
9Kikuya M, Hozawa A, Ohokubo T, et al. Prognostic significance of blood pressure and heart rate variabilities: the Ohasarna study. Hypertension, 2000, 36: 901-906.
10Mena L, Pintos S, Queipo NY, et al. A reliable index for the prognostic significance of blood pressure variability. J Hypertens, 2005, 23: 505-511.